Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.31 |
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
| ▸ | PTGIR | P43119 | 2/20 | 0.30 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15227908 | 0.81 | PPM1D (0.37) | CYP4F2CYP4A11PPM1DDGAT1 | |
| SCHEMBL15115980 | 0.81 | PPM1D (0.37) | CYP4F2CYP4A11PPM1DDGAT1 | |
| SCHEMBL8031542 | 0.78 | CYP4F2 (0.49) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL15237365 | 0.78 | CYP4F2 (0.49) | CYP4F2CYP4A11TSHRALDH1A1LMNA | |
| SCHEMBL8042085 | 0.78 | PPM1D (0.30) | PPM1DDGAT1 | |
| SCHEMBL8045134 | 0.77 | PPM1D (0.32) | PPM1DDGAT1 | |
| SCHEMBL18208695 | 0.74 | LMNA (0.35) | ALDH1A1LMNAPPM1D | |
| SCHEMBL22079855 | 0.74 | PPM1D (0.34) | PPM1D | |
| SCHEMBL15111450 | 0.74 | PPM1D (0.36) | PPM1D | |
| SCHEMBL15241935 | 0.74 | PPM1D (0.36) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-9492496-B2 | Aminothiazoles and their uses | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| WO-2009074605-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | ABAT, AADAT, AADAC | CYP4F2 1847/4885CYP4A11 2229/4885TSHR 3356/4885 |
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, BCAT2 | CYP4F2 553/4885CYP4A11 1201/4885TSHR 3438/4885 |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, BCAT2 | CYP4F2 553/4885CYP4A11 1201/4885TSHR 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.